Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hamdan, Ayad
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	1/2	108	US	AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine	Artiva Biotherapeutics, Inc.	Non Hodgkin Lymphoma	11/24	11/24
Patel, Hitendra
NCT06639724: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer	Recruiting	1	36	US	Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)	University of California, San Diego, Rigel Pharmaceuticals	Pancreatic Ductal Adenocarcinoma (PDAC)	06/27	12/28
Maroge, Joseph
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	1/2	108	US	AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine	Artiva Biotherapeutics, Inc.	Non Hodgkin Lymphoma	11/24	11/24
MK-4002-001, NCT04184050 / 2019-004793-26: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 Data from trial for multiple myeloma at ASH 2022 Dec 2022 - Dec 2022: Data from trial for multiple myeloma at ASH 2022 Data from trial for r/r multiple myeloma at ASH 2022 Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022 Data from trial for multiple myeloma at ASH 2021 Dec 2021 - Dec 2021: Data from trial for multiple myeloma at ASH 2021 results for r/r multiple myeloma Dec 2021 - Dec 2021: results for r/r multiple myeloma Data from trial for multiple myeloma Jun 2021 - Jun 2021: Data from trial for multiple myeloma For the treatment of multiple myeloma Jan 2021 - Jan 2021: For the treatment of multiple myeloma Preliminary data from for r/r multiple myeloma Dec 2020 - Dec 2020: Preliminary data from for r/r multiple myeloma More	Active, not recruiting	1	100	Europe, US	MK-4002, HPN217	Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission	06/25	11/25